Study of Amimaitosai plus steroids for gut graft-versus-host disease
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study tests whether adding an investigational drug called Amimaitosai to standard steroids helps control gut symptoms caused by graft-versus-host disease after a stem cell transplant. It may offer a new option to reduce these symptoms and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older.
- You have a blood cancer that is typically treated with a stem cell transplant.
- You have received a stem cell transplant from a donor.
- You have gastrointestinal symptoms that are caused by graft-versus-host disease.
- Your liver and kidney function must be within certain limits.
- You must not have uncontrolled infections or severe psychiatric disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
This program provides early access to an experimental treatment called MaaT013 for people with severe gut graft-versus-host disease that has not improved with steroids. It aims to help control the condition when other treatments have failed.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests whether giving a fecal transplant (a procedure that transfers healthy bacteria from a donor's stool into your gut) can help children whose gut graft-versus-host disease (a common complication after a stem cell transplant) is not improving with standard steroid treatment.
Hear when a new Acute Gastrointestinal Graft-versus-host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.